- Home
- CHRS vs PIM Comparison
CHRS vs PIM Comparison
Compare CHRS & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PIM
- Stock Information
- Founded
- CHRS 2010
- PIM 1988
- Country
- CHRS United States
- PIM United States
- Employees
- CHRS N/A
- PIM N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PIM Finance Companies
- Sector
- CHRS Health Care
- PIM Finance
- Exchange
- CHRS Nasdaq
- PIM Nasdaq
- Market Cap
- CHRS 156.0M
- PIM 162.3M
- IPO Year
- CHRS 2014
- PIM N/A
- Fundamental
- Price
- CHRS $0.85
- PIM $3.33
- Analyst Decision
- CHRS Buy
- PIM
- Analyst Count
- CHRS 6
- PIM 0
- Target Price
- CHRS $7.10
- PIM N/A
- AVG Volume (30 Days)
- CHRS 3.0M
- PIM 57.5K
- Earning Date
- CHRS 11-04-2024
- PIM 01-01-0001
- Dividend Yield
- CHRS N/A
- PIM 8.28%
- EPS Growth
- CHRS N/A
- PIM N/A
- EPS
- CHRS N/A
- PIM 0.05
- Revenue
- CHRS $308,134,000.00
- PIM N/A
- Revenue This Year
- CHRS $5.18
- PIM N/A
- Revenue Next Year
- CHRS $16.86
- PIM N/A
- P/E Ratio
- CHRS N/A
- PIM $63.80
- Revenue Growth
- CHRS 69.37
- PIM N/A
- 52 Week Low
- CHRS $0.85
- PIM $2.90
- 52 Week High
- CHRS $3.73
- PIM $3.28
- Technical
- Relative Strength Index (RSI)
- CHRS 28.71
- PIM 40.02
- Support Level
- CHRS $0.98
- PIM $3.34
- Resistance Level
- CHRS $1.01
- PIM $3.44
- Average True Range (ATR)
- CHRS 0.08
- PIM 0.03
- MACD
- CHRS -0.01
- PIM -0.01
- Stochastic Oscillator
- CHRS 0.00
- PIM 8.33
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.